Tien Liang Biotech Co., Ltd. Statistics
Tien Liang Biotech Co., Ltd. (4127) Stock Statistics & Valuation Metrics
Total Valuation
Tien Liang Biotech Co., Ltd. has a market cap or net worth of TWD 1.51B. The enterprise value is TWD 2.03B.
- Market Cap
- TWD 1.51B
- Enterprise Value
- TWD 2.03B
Share Statistics
Tien Liang Biotech Co., Ltd. has 45,760,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 45,760,000
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Tien Liang Biotech Co., Ltd.’s return on equity (ROE) is -0.02 and return on invested capital (ROIC) is -1.31%.
- Return on Equity (ROE)
- -0.02
- Return on Assets (ROA)
- -0.01
- Return on Invested Capital (ROIC)
- -1.31%
- Return on Capital Employed (ROCE)
- -0.03
- Revenue Per Employee
- 5.82M
- Profits Per Employee
- -116.49K
- Employee Count
- 88
- Asset Turnover
- 0.43
- Inventory Turnover
- 3.49
Valuation Ratios
The current PE Ratio of Tien Liang Biotech Co., Ltd. is 23.02. Tien Liang Biotech Co., Ltd.’s PEG ratio is -0.00.
- PE Ratio
- 23.02
- PS Ratio
- 2.45
- PB Ratio
- 3.06
- Price to FCF
- 42.42
- Price to Operating Cash Flow
- 26.32
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Tien Liang Biotech Co., Ltd. had revenue of 511.79M and earned -10.25M in profits. Earnings per share was -0.22.
- Revenue
- 511.79M
- Gross Profit
- 277.86M
- Operating Income
- -16.14M
- Pretax Income
- -11.75M
- Net Income
- -10.25M
- EBITDA
- -6.07M
- Earnings Per Share (EPS)
- -0.22
Cash Flow
In the last 12 months, operating cash flow was 60.37M and capital expenditures -22.83M, giving a free cash flow of 37.54M billion.
- Operating Cash Flow
- 60.37M
- Free Cash Flow
- 37.54M
- Free Cash Flow per Share
- 0.82
Dividends & Yields
Tien Liang Biotech Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 2.38%
- Earnings Yield
- 4.39%
Stock Price Statistics
- Beta
- 0.32
- 52-Week Price Change
- 3.28%
- 50-Day Moving Average
- 48.10
- 200-Day Moving Average
- 53.69
- Relative Strength Index (RSI)
- 25.21
- Average Volume (3m)
- 294.41K
Important Dates
Tien Liang Biotech Co., Ltd. upcoming earnings date is Nov 12, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Nov 12, 2025
- Next Earnings Date
- Nov 12, 2026
- Ex-Dividend Date
- ―
Financial Position
Tien Liang Biotech Co., Ltd. as a current ratio of 0.40, with Debt / Equity ratio of 126.26%
- Current Ratio
- 0.40
- Quick Ratio
- 0.31
- Debt to Market Cap
- 0.42
- Net Debt to EBITDA
- -78.48
- Interest Coverage Ratio
- -1.45
Taxes
In the past 12 months, Tien Liang Biotech Co., Ltd. has paid -1.50M in taxes.
- Income Tax
- -1.50M
- Effective Tax Rate
- 0.13
Enterprise Valuation
Tien Liang Biotech Co., Ltd. EV to EBITDA ratio is 49.21, with an EV/FCF ratio of 53.47.
- EV to Sales
- 3.08
- EV to EBITDA
- 49.21
- EV to Free Cash Flow
- 53.47
- EV to Operating Cash Flow
- 33.25
Balance Sheet
Tien Liang Biotech Co., Ltd. has TWD 197.10M in cash and marketable securities with TWD 598.00M in debt, giving a net cash position of -TWD 400.89M billion.
- Cash & Marketable Securities
- TWD 197.10M
- Total Debt
- TWD 598.00M
- Net Cash
- -TWD 400.89M
- Net Cash Per Share
- -TWD 8.76
- Tangible Book Value Per Share
- TWD 11.37
Margins
Gross margin is 57.88%, with operating margin of 0.87%, and net profit margin of 10.62%.
- Gross Margin
- 57.88%
- Operating Margin
- 0.87%
- Pretax Margin
- 10.64%
- Net Profit Margin
- 10.62%
- EBITDA Margin
- 6.27%
- EBIT Margin
- 4.56%
Analyst Forecast
The average price target for Tien Liang Biotech Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 52.12%
- EPS Growth Forecast
- ―
